CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The project focuses on developing AT-001, a new drug aimed at stopping and reversing dementia by preventing the aggregation of amyloid and tau proteins. Utilizing a precision medicine platform that incorporates Big Data and artificial intelligence, it targets patients with specific biomarkers to improve treatment outco…
With an aging population and >55 million dementia cases worldwide; treatments are more needed than ever.
However, effective treatments are lacking, with solutions only stalling dementia progress and no real disease-modifying effect. ATI has developed AT-001, a new drug with the potential to stop and revert the disease, and to delay its onset. AT-001 has been developed through the DNACA precision-medicine based platform, which applies Big Data mining and Deep Learning/AI algorithms to identify pa…
ARCTIC THERAPEUTICS EHF
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
